Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 15/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.55 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26315870 | 0.88 | RBP4 (0.78) | RBP4CYP2C9SLC9A1CYP2C19SCD5 | |
| SCHEMBL16689594 | 0.87 | RBP4 (1.00) | RBP4CYP2C9SLC9A1CYP2C19SCD5 | |
| SCHEMBL29597041 | 0.87 | RBP4 (0.79) | RBP4CYP2C9SLC9A1CYP2C19SCD5 | |
| SCHEMBL20589812 | 0.87 | RBP4 (0.79) | RBP4CYP2C9SLC9A1CYP2C19SCD5 | |
| SCHEMBL16689566 | 0.87 | RBP4 (0.67) | RBP4CYP2C9SLC9A1CYP2C19 | |
| SCHEMBL29598202 | 0.86 | RBP4 (0.77) | RBP4CYP2C9SLC9A1CYP2C19SCD5 | |
| SCHEMBL17505297 | 0.86 | RBP4 (0.77) | RBP4CYP2C9SLC9A1CYP2C19SCD5 | |
| SCHEMBL16689596 | 0.85 | RBP4 (1.00) | RBP4CYP2C9SLC9A1CYP2C19SCD5 | |
| SCHEMBL16689574 | 0.84 | RBP4 (0.67) | RBP4CYP2C9SLC9A1CYP2C19SCD5 | |
| SCHEMBL16689562 | 0.84 | RBP4 (0.67) | RBP4SCD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160287607-A1 | NON-RETINOID ANTAGONISTS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-10-06 | — | — | US | disclosed |
| US-9333202-B2 | Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-05-10 | — | — | US | disclosed |
| US-20150126494-A1 | NON-RETINOID ANTAGONISTS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126494-A1 | NON-RETINOID ANTAGONISTS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | RBP4, RBP1, LRAT | RBP4 1/4885CYP2C9 4885/4885SLC9A1 1109/4885 |
| US-20160287607-A1 | NON-RETINOID ANTAGONISTS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | RBP4, RBP1, LRAT | RBP4 1/4885CYP2C9 4885/4885SLC9A1 1109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.